We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
Read MoreHide Full Article
Bausch Health Companies Inc.’s (BHC - Free Report) dermatology business, Ortho Dermatologics, announced that the FDA has approved the New Drug Application for its acne lotion Arazlo (tazarotene).
Arazlo Lotion 0.045% has been approved for the topical treatment of acne vulgaris in patients nine years of age or older.
The approval was based on two phase III multicenter, randomized, double-blind, vehicle-controlled clinical trials in 1,614 patients with moderate-to-severe acne. In both studies, all primary efficacy endpoints were met with statistical significance. Arazlo was also generally well-tolerated in the clinical study population.
The approval will broaden Bausch’s dermatology portfolio, expanding its acne portfolio to help approximately 50 million Americans who are affected by this prevalent skin condition. Per the company, Arazlo is the first tazarotene acne treatment available in a lotion form.
The Ortho Dermatologics business comprises treatments for a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The business consists of Duobrii, Bryhali and Siliq product lines as well.
Bausch is on track to build its psoriasis and acne product portfolios, with a focus on topical gel and lotion products over injectable biologics as they promise potential. The company recently expanded its Ortho Dermatologics sales force to drive growth.
Bausch’s stock has surged 61.9% in the year so far compared with the industry’s growth of 6.8%.
Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company expects the top line to get a boost. Bausch + Lomb/International and Salix segments maintain momentum on the back of several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, continue to perform well too.
Alkermes’ earnings per share estimates have increased from 37 cents to 52 cents for 2019 in the past 60 days.
Anika’s earnings per share estimates have increased from $1.75 to $2.03 for 2019 in the past 60 days.
Innoviva’s earnings per share estimates have increased from $1.71 to $2.03 for 2019 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
Bausch Health Companies Inc.’s (BHC - Free Report) dermatology business, Ortho Dermatologics, announced that the FDA has approved the New Drug Application for its acne lotion Arazlo (tazarotene).
Arazlo Lotion 0.045% has been approved for the topical treatment of acne vulgaris in patients nine years of age or older.
The approval was based on two phase III multicenter, randomized, double-blind, vehicle-controlled clinical trials in 1,614 patients with moderate-to-severe acne. In both studies, all primary efficacy endpoints were met with statistical significance. Arazlo was also generally well-tolerated in the clinical study population.
The approval will broaden Bausch’s dermatology portfolio, expanding its acne portfolio to help approximately 50 million Americans who are affected by this prevalent skin condition. Per the company, Arazlo is the first tazarotene acne treatment available in a lotion form.
The Ortho Dermatologics business comprises treatments for a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The business consists of Duobrii, Bryhali and Siliq product lines as well.
Bausch is on track to build its psoriasis and acne product portfolios, with a focus on topical gel and lotion products over injectable biologics as they promise potential. The company recently expanded its Ortho Dermatologics sales force to drive growth.
Bausch’s stock has surged 61.9% in the year so far compared with the industry’s growth of 6.8%.
Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company expects the top line to get a boost. Bausch + Lomb/International and Salix segments maintain momentum on the back of several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, continue to perform well too.
Zacks Rank & Stocks to Consider
Bausch currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare space are Alkermes, Inc. (ALKS - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Innoviva Inc. (INVA - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ earnings per share estimates have increased from 37 cents to 52 cents for 2019 in the past 60 days.
Anika’s earnings per share estimates have increased from $1.75 to $2.03 for 2019 in the past 60 days.
Innoviva’s earnings per share estimates have increased from $1.71 to $2.03 for 2019 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>